Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HCM NASDAQ:INDV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHCMHUTCHMED$11.53+2.9%$11.05$9.77▼$18.79$2.01B0.2442,330 shs34,733 shsINDVIndivior$40.67-0.8%$39.02$17.10▼$42.81$4.96B0.862.15 million shs863,499 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHCMHUTCHMED+0.72%+0.18%+9.86%-16.17%-37.71%INDVIndivior+2.40%+1.33%-2.01%+20.03%+139.85%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHCMHUTCHMED$11.53+2.9%$11.05$9.77▼$18.79$2.01B0.2442,330 shs34,733 shsINDVIndivior$40.67-0.8%$39.02$17.10▼$42.81$4.96B0.862.15 million shs863,499 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHCMHUTCHMED+0.72%+0.18%+9.86%-16.17%-37.71%INDVIndivior+2.40%+1.33%-2.01%+20.03%+139.85%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHCMHUTCHMED 2.33Hold$14.8730.63% UpsideINDVIndivior 2.71Moderate Buy$43.676.53% UpsideCurrent Analyst Ratings BreakdownLatest HIK, INDV, HCM, and AGY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/24/2026INDVIndivior Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C) ➝ Hold (C+)7/23/2026HCMHUTCHMED The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$16.00 ➝ $14.007/17/2026HCMHUTCHMED Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)7/9/2026INDVIndivior Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C+) ➝ Hold (C)7/7/2026HCMHUTCHMED Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$20.00 ➝ $17.006/29/2026HCMHUTCHMED Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)6/29/2026INDVIndivior Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/23/2026INDVIndivior Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C) ➝ Hold (C+)6/18/2026INDVIndivior BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$46.006/18/2026INDVIndivior BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$46.005/28/2026HCMHUTCHMED Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$13.60(Data available from 7/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHCMHUTCHMED$548.51M3.62$2.76 per share4.13$7.17 per share1.59INDVIndivior$1.24B4.03$2.78 per share14.72($0.78) per share-52.55Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHCMHUTCHMED$456.91MN/AN/A40.65N/AN/AN/AN/A7/30/2026 (Estimated)INDVIndivior$210M$1.9521.019.60N/A19.44%-219.26%29.40%8/4/2026 (Estimated)Latest HIK, INDV, HCM, and AGY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/4/2026Q2 2026INDVIndivior$0.9220N/AN/AN/A$307.55 millionN/A7/30/2026H1 2026HCMHUTCHMED$0.1450N/AN/AN/A$304.16 millionN/A4/30/2026Q1 2026INDVIndivior$0.64$0.96+$0.32$3.45$272.84 million$317.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthHCMHUTCHMEDN/AN/AN/AN/AN/AINDVIndiviorN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHCMHUTCHMED0.054.964.83INDVIndiviorN/A0.860.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHCMHUTCHMED8.82%INDVIndivior60.33%Insider OwnershipCompanyInsider OwnershipHCMHUTCHMED3.60%INDVIndivior0.74%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHCMHUTCHMED1,796174.47 million168.19 millionNot OptionableINDVIndivior1,051121.92 million121.02 millionNot OptionableHIK, INDV, HCM, and AMYT HeadlinesRecent News About These CompaniesIndivior to Report Second Quarter 2026 Financial Results and Host WebcastJuly 23, 2026 | globenewswire.comIndivior (INDV) Projected to Announce Quarterly Earnings on ThursdayJuly 23, 2026 | marketbeat.comBillionaire Investor Howard Marks' Top 5 Holdings: A Buy at These Prices?July 21, 2026 | 247wallst.comIndivior (NASDAQ:INDV) Insider Christian Heidbreder Sells 18,586 SharesJuly 14, 2026 | insidertrades.comIndivior (NASDAQ:INDV) Insider Christian Heidbreder Sells 18,586 Shares of StockJuly 13, 2026 | marketbeat.comIndivior Posts Strong Q1 Results, Raises 2026 OutlookJuly 7, 2026 | theglobeandmail.comIndivior Pharmaceuticals Inc. (INDV) is on the move, here's why the trend could be sustainableJune 29, 2026 | msn.comZacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and MarkerJune 26, 2026 | zacks.comIndivior PLC Ordinary SharesJune 25, 2026 | 247wallst.com5 Small Drug Stocks to Invest in Amid a Biotech ComebackJune 25, 2026 | zacks.comIndivior gains new overweight at Barclays on business turnaroundJune 18, 2026 | msn.comHow Investors Are Reacting To Indivior (INDV) Upgraded 2026 Outlook And $175 Million Buyback PlanJune 15, 2026 | finance.yahoo.comIs Indivior Pharmaceuticals, Inc. (INDV) A Good Stock To Buy Now?June 13, 2026 | insidermonkey.comRecent price trend in Indivior Pharmaceuticals Inc. (INDV) is your friend, here's whyJune 12, 2026 | msn.comINDV and the Shift to Long-Acting Opioid Use Disorder Care in 2026June 12, 2026 | zacks.comIs Indivior Stock a Buy After Higher 2026 Guidance?June 12, 2026 | zacks.comINDV Stock: What Sublocade Growth Signals for 2026June 12, 2026 | zacks.comIndivior (NASDAQ:INDV) CFO Sells $1,357,200.00 in StockJune 11, 2026 | insidertrades.comIndivior: A Stronger Business Than When I First Covered ItJune 9, 2026 | seekingalpha.com5 Top-Ranked Efficient Stocks Beating Industry Peers on Key MetricsJune 2, 2026 | zacks.comWhat to Know About This Fund's $74.8 Million Indivior SaleMay 30, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Charts That Could Change the Course of Summer TradingBy Thomas Hughes | July 1, 2026Silicon Starvation: Amazon Feasts on Legacy GPUsBy Jeffrey Neal Johnson | July 7, 2026Stacking Chips: The Hidden Supply Shock Fueling IntelBy Jeffrey Neal Johnson | July 8, 2026CPI Comes In Cool: Why It Could Revive These 3 Rate-Sensitive StocksBy Dan Schmidt | July 15, 2026Insiders Sell 2 AI Enablers: Investors Can Buy Into Their FuturesBy Thomas Hughes | July 14, 2026HIK, INDV, HCM, and AMYT Company DescriptionsHUTCHMED NASDAQ:HCM$11.52 +0.33 (+2.90%) As of 03:17 PM Eastern This is a fair market value price provided by Massive. Learn more.HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.Indivior NASDAQ:INDV$40.62 -0.37 (-0.90%) As of 03:19 PM Eastern This is a fair market value price provided by Massive. Learn more.Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why SK hynix Could Be the Best AI Chip Stock to Buy Now Why Bloom Energy May Be the Most Important AI Infrastructure Stock Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead? Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters Broadcom’s $200 Billion Samsung Deal Shows How Costly the AI Memory Race Has Become Meta’s AI Spending Problem Just Found a BlackRock Solution Carrier Earnings Could Send the Stock to a New All-Time High Amazon’s Satellite Push Raises the Stakes for SpaceX and AST SpaceMobile Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
